{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035686","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.141441+00:00","generated_at":"2026-05-29T22:39:43.987835+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity: Two stenoparib patients exceed 14 months; $18.5M cash; lab services revenue","bullets":["Two advanced ovarian cancer patients on stenoparib Phase 2 trial beyond 14 months, a notable duration given heavy pretreatment.","Cash balance of $18.5M as of Sept 30, 2024, sufficient to initiate registrational trial toward FDA approval.","Allarity Medical Lab signs external service agreements for DRP and gene expression analysis with multiple biotech firms.","Revenue from lab services reduces overall lab cost base and advances DRP platform in oncology field."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035686","json":"https://secwatch.observer/filing/0001437749-24-035686.json","markdown":"https://secwatch.observer/filing/0001437749-24-035686.md","text":"https://secwatch.observer/filing/0001437749-24-035686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924035686/0001437749-24-035686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924035686/allr20241118_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:39:43.987835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}